INTRODUCTION
The treatment of coronary atherosclerosis is a major global health care expenditure. A substantial component of this expenditure is attributable to patients undergoing percutaneous coronary intervention or coronary artery bypass graft (CABG) surgery, with >160,000 CABG procedures performed annually in the United States alone (1) . Veins are common conduits used in these surgical procedures; however, about 40% of vein grafts will fail within 12 to 18 months of implantation (2) . This high failure rate is attributable to adverse vascular remodeling, yet the disease mechanisms regulating the pathophysiological changes involved remain poorly understood (3) . Vascular remodeling is the result of the complex, dynamic interactions between various cell populations, including endothelial cells, mesenchymal smooth muscle-type cells, activated thrombocytes, and infiltrating inflammatory cells (4) (5) (6) . The cellular contributions to the remodeled vessels are generally considered to be lineage-restricted (7) , although the origin of the cells forming the neointima is highly controversial (8) .
Endothelial-to-mesenchymal transition (EndMT) is the process by which endothelial cells lose their cell-specific markers and morphology and acquire a mesenchymal cell-like phenotype. EndMT is regulated by a complex orchestration of several signaling pathways (9) and has been implicated in chronic fibrosis (10) and in heterotopic ossification owing to fibrodysplasia ossificans progressiva (11) . Recent studies indicate that EndMT may be involved in murine transplant arteriopathy (12) , in the rejection of human transplant lesions (12) , and in vascular cerebral cavernous malformations (13) . However, the role of EndMT and the mechanisms regulating cell phenotype adaptation during human vein graft remodeling are poorly understood.
Here, we investigated EndMT during the neointimal hyperplasic response that occurs after grafting veins into the arterial circulation in both mice and humans. We demonstrated that endothelial lineagederived cells comprise most vascular neointimal cells that formed during murine vein graft remodeling. Early failed human grafts also displayed features indicative of EndMT. Furthermore, we show that the transforming growth factor-b (TGF-b)-Smad2/3-Slug signaling pathway plays a pivotal role in regulating vein graft EndMT, with in vivo reduction of TGF-b signaling decreasing both neointimal formation and the relative contribution of endothelial lineage-derived cells to the neointima. These findings enhance our understanding of the molecular mechanisms underlying vascular remodeling and reveal novel targets for potential therapeutic interventions aimed at improving clinical outcomes after interpositional vein grafting.
RESULTS
Endothelial lineage-derived cells contribute to neointimal formation during vascular remodeling in mice To examine the contribution of endothelial-derived cells to the neointima during vascular remodeling, interpositional vein grafting was performed using two independent endothelial lineage tracing systems: the constitutive Endotrack YFP or Endotrack LacZ (14) (15) (16) and the tamoxifen-inducible Ind.Endotrack YFP transgenic mouse models (17) . In these models, endothelial-specific cre gene expression irrevocably activates the reporter gene, resulting in continuous YFP or LacZ gene expression regardless of subsequent changes in cellular phenotype (10, (14) (15) (16) (17) (18) (19) . Before grafting, yellow fluorescent protein (YFP) expression within the jugular vein and perivascular region was observed in 98. 5 S1A ). YFP expression in native, ungrafted jugular veins was only observed in endothelial cells, which also stained positive for the endothelial cell marker CD31 ( fig. S1A ).
We grafted a branch of the jugular vein from the endothelial lineagetracing mouse models into the femoral artery of genetically matched wild-type recipients through end-to-end anastomosis (20) . Graft placement with chronic exposure to arterial pressure induced a remodeling program, leading to neointimal formation. Endothelial-derived YFPpositive (YFP + ) cells were recruited to the neointima, representing 51.7 ± 3.3% and 27.8 ± 2.9% (SEM) of the total neointimal cell population at day 35 in the Endotrack YFP and Ind.Endotrack YFP veins, respectively (Fig. 1A) . These findings were confirmed in long-term fate-tracking experiments, where endothelial-derived cells persisted and contributed to the neointima, at least until 90 days after transplantation ( fig. S1B) . Consistent with other mouse models of neointimal formation (4, 5), we found a progressive increase in the total number of neointimal cells between 3 and 14 days after vein grafting (Fig. 1B) . Whereas the number of nonendothelial lineage (YFP − ) neointimal cells plateaued after 14 days, the number of neointimal YFP + cells continued to increase up to 35 days after grafting (Fig. 1B) . Similar to a previous report (21) , we detected cell cycle reentry of YFP + cells (Fig. 1C and fig. S1 , D and E). There was a very low possibility that donor-derived YFP + hematopoietic cells contribute to vascular remodeling. Nevertheless, we analyzed ungrafted jugular veins before transplantation by fluorescence-activated fig. S3 , A to C), indicating that donor hematopoietic cells do not populate the vein graft or its neointima. We excluded possible non-endothelialdependent Tie2 promoter activation using the transgenic Tie2GFP mouse line in which green fluorescent protein (GFP) is expressed transiently when the Tie2 promoter is active ( fig. S3D) (22) . These experiments demonstrate that endothelial lineage-derived cells contribute to neointimal formation during vein graft remodeling.
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We addressed the phenotypic fate of the vein graft endothelium with respect to neointimal formation. Staining for three endothelial-specific markers (CD31, VE-cadherin, and endoglin) revealed that neointimal, but not luminal, YFP + cells progressively lost expression of these markers between 7 and 14 days after grafting (Fig. 2, A and B) . With the exception of luminal cells, we did not detect expression of endothelial-specific markers on neointimal YFP + cells at day 35. We examined YFP + cells for coexpression of early vascular smooth muscle cell (VSMC) markers, smooth muscle actin (SMA) and SM22a, and the mature markers calponin, smoothelin, and VSMC-specific myosin heavy chain (SM-MHC). At day 0, no YFP + cells were detected that coexpressed any VSMC markers ( To further confirm that a proportion of neointimal cells were derived from endothelial cells, we used a smooth muscle cell-specific lineage-tracing model Ind.SMCtrack YFP (23 fig. S5B ), which, on the basis of the recombination efficiency of this mouse model, suggests that 16% of the neointimal cells were of VSMC origin.
Adventitial fibroblasts have also been attributed to neointimal formation during vascular remodeling (24) ; however, we were unable to detect a significant number of YFP + cells that coexpressed the fibroblast markers fibroblast-specific protein 1 (FSP-1) or fibroblast activation protein a (FAP) in the TGF-b signaling is activated during vascular remodeling TGF-b signaling in vascular remodeling is well documented (25) (26) (27) and has been implicated in EndMT during development and fibrotic remodeling (18, 28) . In endothelial cells, TGF-b is known to mediate the sequential phosphorylation of ALK5 and Smad2/3, but its impact on ALK1 and Smad1/5/8 signaling remains controversial (29, 30) . Murine jugular vein endothelial cells expressed TGFbRI/Alk5, TGFbRII, and ALK1 ( fig. S8A ). In grafted veins, phosphorylated Smad2/3 (p-Smad2/3) was detected in endothelial cells at days 3 and 7 after grafting, which declined by day 14 and was undetectable by day 35 ( Fig. 3A and fig. S8B ). Individual p-Smad3 and p-Smad2 immunostaining showed similar activation as p-Smad2/3 ( fig. S8C ). In contrast, p-Smad1/5/8 was evident as early as 3 days after grafting but was present throughout the 35-day observation period in YFP + cells (Fig. 3A and fig. S8 , C and D). Next, we quantified the expression of established TGF-b-regulated transcription factors implicated in developmental EndMT: Slug, Twist, and Snail (31) . Slug and Twist were activated predominantly in YFP + cells from 3 to 14 days after vein grafting, but were absent by day 35 (Fig. 3B and fig. S9, A and B) . Conversely, in the early phase of remodeling (days 0 to 7), activation of Snail was barely detectable but was evident at day 35 after grafting, where it was primarily restricted to YFP − cells ( fig. S9C ). Immunoblotting using individual p-Smad and Slug antibodies corroborated the immunostaining data (Fig. 3C) . The transient activation of Smad2/3 is consistent with the up-regulation of Twist and Slug, and supports our hypothesis that TGF-b signaling triggers endothelial cell phenotypic fate changes during vein graft remodeling. TGF-b-Smad2/3 signaling modulates EndMT during vein graft remodeling The role of TGF-b in vein graft remodeling and the initiation of EndMT were investigated in vivo. Recipient mice were pretreated with pan-TGF-b neutralizing antibody before grafting Endotrack YFP veins that were also treated by immersion in pan-TGF-b neutralizing antibody or control immunoglobulin G (IgG) ex vivo before grafting. Inhibition of TGF-b1 was verified by measuring plasma levels of total TGF-b1 (Fig. 4A) and by confirming diminished activation of Smad2/3 at the 7-day time point (fig. S12A ). Consistent with our hypothesis, blocking TGF-b signaling inhibited EndMT by reducing neointimal area and YFP + cell contribution by day 35 compared to IgGtreated controls (Fig. 4, B to D) . TGF-b inhibition did not substantially alter the extracellular matrix composition (fig. S12B ). (Fig. 5) .
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We next tested whether the inhibition of Smad2 or Smad3 signaling in vein grafts altered the expression of Snail, Slug, and Twist, as well as Smad-dependent activators of the mesenchymal program, myocardin, and myocardin-related factor a (MRFa) and MRFb. These experiments revealed that Smad3 knockdown significantly attenuated the expression of Slug and MRFb at the 3-and 7-day early time points ( fig. S13B ). Smad2 knockdown attenuated only the expression of Slug, whereas changes in MRFb expression did not reach statistical significance (fig. S13B). We used chromatin immunoprecipitation to demonstrate the direct binding of Smad3 to the Slug promoter both in vitro ( fig. S13C) and in vivo (fig. S13D) (Fig. 6, A and B) . Activation of Smad3, but not Smad1/5/8, was significantly decreased in these grafts ( fig. S14 ). Lentiviral-mediated overexpression of Slug rescued the effect of Smad3 haploinsufficiency on neointimal formation and EndMT after vein grafting (Fig. 6C) . The role of endothelial Smad2 was examined in the Smad2
Fl/Fl ;Ind.Endotrack YFP line. Depletion of endothelial Smad2 resulted in more favorable vascular remodeling and reduced EndMT (Fig. 6D) . These findings are consistent with our Smad3 and Smad2 shRNA knockdown data (Figs. 4 and 5) and support the important role of Smad2/3 in TGF-bdependent EndMT during vein graft remodeling.
EndMT is observed in human endothelial cells and in human vein graft remodeling
We confirmed by FACS analysis that TGFbRII, TGFbR1/Alk5, and Alk1 are expressed in human umbilical vein endothelial cells (HUVECs) (fig. S15A ). HUVECs treated with TGF-b1 showed increased expression of SM22a and Slug, and decreased expression of CD31 and VE-cadherin, compared with no treatment (Fig. 7A) To better understand the role of EndMT in human vein graft remodeling, we evaluated histological sections from newly acquired early-phase failed (<1 year, n = 5) and long-term patent vein grafts (>6 years, n = 5) stained with multiple endothelial cell markers (VE-cadherin, vWF, and CD31) and immature (SMA and SM22a) or mature VSMC markers (SM-MHC and calponin). A subset of cells in the early vein graft neointimas costained for both endothelial and immature SMC markers, but not for mature VSMC markers (Fig. 7C , top panels), indicating that endothelial cells transition and acquire a VSMC-like phenotype during human vein graft remodeling. In the long-term patent grafts, only the luminal endothelial cells stained for endothelial cell markers, and no double-positive cells were observed in the neointima (Fig.  7C, bottom panels) . The human data corroborate our murine studies and underscore a role for EndMT in both human and mouse vein graft remodeling.
DISCUSSION
Here, we present evidence that EndMT is a central component of the vascular remodeling that occurs during vein adaptation to the arterial circulation in a murine model. At 35 days after vein grafting, half of the cells populating the neointima were of endothelial origin. These endothelial-derived cells lost their endothelial phenotype and acquired smooth muscle cell-like properties, yet failed to develop a fully "mature" smooth muscle cell phenotype. We provide a mechanistic model demonstrating that TGF-b-Smad2/3-Slug signaling is a principal pathway regulating EndMT during vein graft remodeling. Examination of postmortem human vein graft tissue confirmed that the process of EndMT is operative in human vein graft remodeling. Together, these data identify new pathways regulating vascular remodeling that may be targeted for clinical interventions to improve outcomes after interpositional vein grafting in humans.
Supporting our in vitro findings, Medici et al. recently showed that TGF-b signaling promotes Snail-mediated EndMT via both Smaddependent and Smad-independent signaling (32), and studies using murine models have shown that endothelial cells participate in cardiac fibrosis via EndMT (11, 18) . It is well known that during development, TGF-b-mediated signaling contributes to emerging mesenchymal cell populations. Therefore, this study and others collectively support the hypothesis that TGF-b-mediated developmental programs are reactivated in response to injury or disease, and we propose that adult vein graft neointimal formation represents yet another biological setting where EndMT contributes to cardiovascular pathogenesis. Treatment The use of genetically engineered mouse models enabled us to identify the cellular origins and molecular mechanisms contributing to the underlying pathology of vein graft remodeling, which is currently not possible with larger animal models or with humans. The cellular origins of the neointima during vascular remodeling have, in part, been attributed to differences in surgical technique (34) . The vascular remodeling that occurs in end-to-end anastomoses differs from end-to-side anastomoses in that the neointima in the former is composed primarily of donor-derived cells, whereas that in the latter is composed primarily of recipient-derived cells (35, 36) . Our study used end-to-end anastomoses to graft a branch of the jugular vein into the femoral artery. This technique resulted in substantial donor endothelial cell preservation, despite the increase in graft diameter and initial disruption of the venous endothelial layer because of increased arterial pressure. Although it may be argued that the combination of pressure-induced disruption of the endothelial cell layer with the preservation of select endothelial cell groups may facilitate EndMT, other dissimilarities between these vein graft models remain to be defined to account for the differing neointimal cellular contributions. Among the established murine vein graft models, our surgical model most closely replicates clinical veinto-arterial grafting (34) .
However, there are inherent differences between mouse and human anatomy and physiology, including differences in size, heart rate, and hemodynamic output, limiting the degree to which one can extrapolate these findings to human vein graft remodeling. For example, unlike human veins, mouse veins consist of a considerably thinner smooth muscle cell layer; the distending forces of acute-onset arterial pressure and flow might induce different degrees of vascular damage in comparison to human vein grafts. Further, because of size disparity, different surgical techniques are used to transplant mouse versus human veins, which may affect the remodeling process. Furthermore, endothelial cell lineage-tracing studies are not feasible in humans; therefore, we examined postmortem failed and long-term patent vein grafts. Corroborating our in vitro and murine studies, early-phase human vein grafts displayed molecular features that were strongly suggestive of EndMT.
In summary, our findings contribute to the greater understanding of the molecular mechanisms underlying human vascular remodeling and reveal novel targets against which potential therapeutic interventions can be developed for improving clinical outcomes after interpositional vein grafting. Toward translation, in a clinical study, treatment with the angiotensin II receptor blocker losartan significantly slowed the rate of pathologic aortic root dilation in a small cohort of pediatric patients with Marfan syndrome (37) . From the perspective of attenuating vein graft neointimal formation, given that TGF-b signaling is upregulated within hours after vein graft surgery (38) and that neointimal formation plateaus and slows over the ensuing weeks and months, we speculate that the optimal window for clinical therapeutic intervention with anti-TGF-b therapies may be perioperative and continued in the subsequent 2 to 6 weeks after graft surgery. Translation to the clinic will first require additional proof-of-concept studies in larger animal models to confirm the potential clinical benefit of modulating the TGF-b signaling pathway after vein graft surgery. These findings contribute to the greater understanding of the molecular mechanisms underlying human vascular remodeling and reveal novel targets that may be translated into potential therapeutic interventions to improve clinical outcomes after interpositional vein grafting.
MATERIALS AND METHODS
Study design
The study objective was to use in vivo endothelial cell lineage-tracing murine models to track and quantify donor vein endothelial cells grafted into the arterial circulation, characterize the molecular mechanisms regulating EndMT, and identify potential therapeutic targets. For all surgeries, numerical identifiers linking genotype/treatment of the donor sample were blinded to the scientist assessing/quantifying the results (for example, counting costained cells). All experiments were replicated as indicated. The 3-, 7-, 14-, and 35-day time points were selected on the basis of (20) , and our preliminary studies showed that there is no additional neointimal formation after the 35-day time point. A minimum of four patent mouse vein grafts were used in data analysis. Postmortem human samples were selected on the basis of available samples that most closely approximated the mouse time points. Anonymized unstained sections of paraffin-embedded human saphenous vein grafts were available from the CVPath Institute Sudden Coronary Death registry (CVPISCDRr) from hearts submitted in consultation (39) .
Generation of animals
The National Heart, Lung, and Blood Institute (NHLBI) Animal Care and Use Committee approved all animal experiments. Primers used for genotyping are listed in Induction of cre gene was achieved in 4-week-old mice by intraperitoneal injection of 1 mg of tamoxifen dissolved in 100 ml of sterile peanut oil once daily for 1 week, followed by 1 week off, then a second course of injections daily for 1 week.
Vein grafting
Vein graft surgeries were performed as described in (20) , where a vein graft was interpositioned via end-to-end anastomoses, as detailed in Supplementary Materials and Methods.
Immunostaining
For immunostaining on fresh-frozen tissues, thawed slides were washed in phosphate-buffered saline (PBS) and blocked using 5% donkey serum in PBS with 0.1% Triton X-100. For staining on formalin-fixed, paraffin-embedded human samples, slides were deparaffinized and underwent antigen retrieval. After blocking, primary antibodies were applied in 3% bovine serum albumin overnight at 4°C, followed by the corresponding secondary antibody for 1 hour at room temperature. Primary antibodies are shown in table S2. Nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI). Control slides were routinely stained in parallel by substituting IgG or the specific IgG isotype. Protocol for BrdU immunolabeling is detailed in Supplementary Materials and Methods. All images were acquired using either a Zeiss Axioscope with AxioVision v4.3 software, a Zeiss LSM 510 UV laser scanning confocal microscope (Carl Zeiss GmbH), or Nikon Eclipse TE300 inverted fluorescence microscope.
Counting of costained cells
Slides were scanned with a confocal microscope, as described, at the stated magnification. Images were analyzed in a blinded manner. Specimen areas were divided into numbered grids, and every cell pertaining to the neointimal region within the grid was counted. Total cell number within each grid was assessed by DAPI staining. Antibody-specific staining was assessed with filters specific for the corresponding secondary antibody fluorophore. YFP + cells were counted from images manually and expressed as the number of YFP + cells relative to total neointimal cells.
Morphology of neointima and cell counting
For morphological analysis of neointimal area, we first determined the ideal luminal area by calculating the area within the perimeter of the internal elastic lamina. Next, we measured the luminal area within the neointima (residual lumen). The difference between these values represents the neointimal area.
Cell lines and culture conditions HUVECs (Lonza) and mEOMA cells (American Type Culture Collection) were maintained according to the manufacturer's instructions, detailed in Supplementary Materials and Methods.
shRNA transfection shRNA constructs for Smad3, Smad2, and scrambled controls were purchased from Open Biosystems, prepared according to the manufacturer's protocol, and used as described in Supplementary Materials and Methods.
Neutralizing anti-TGF-b antibody treatment Recipient mice were injected intraperitoneally with neutralizing anti-pan-TGF-b (10 mg/kg) (Sigma) or control IgG 1 day before surgery, and every 2 weeks thereafter. Donor veins were pretreated with neutralizing antibody (1 mg/ml) or control IgG for 4 hours at room temperature. Total TGF-b1 from plasma at specified time points was measured by enzyme-linked immunosorbent assay according to the manufacturer's instructions (R&D Systems).
RNA extraction, reverse transcription, and real-time polymerase chain reaction RNA was isolated from cultured cells with the RNeasy kit (Qiagen) according to the manufacturer's instructions. Table S1 . Primers used. Table S2 . Antibodies used.
